Navigation Links
Pharmaxis Announces Placement of $47 Million and Share Purchase Plan
Date:6/3/2009

oking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

    CONTACT:

     Alan Robertson - Chief Executive Officer
     Tel:   +61-2-9454-7200
     Email: alan.robertson@pharmaxis.com.au

    RELEASED THROUGH:

    Australia:
     Felicity Moffatt
     Tel:   +61-418-677-701
     Email: felicity.moffatt@pharmaxis.com.au

    United States:
     Brandon Lewis, Trout Group
     Tel:   +1-646-378-2915
     Email: blewis@troutgroup.com

'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. New Pharmaxis Board Appointment
2. Pharmaxis Investor Conference Call
3. Pharmaxis Appoints French Distributor for Aridol(TM)
4. Pharmaxis Builds Senior Management Team
5. Pharmaxis Investor Conference Call
6. Pharmaxis Aridol Approved for Sale in Switzerland
7. Pharmaxis Investor Conference Call
8. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
9. New Pharmaxis Board Appointment
10. Pharmaxis Aridol Authorised for Sale in Germany
11. Pharmaxis First Steps into China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... , March 6, 2015 ... Repair Market by Product (Mesh/Tissue patch, Allograft, Xenograft, Suture ... Orthopedic, Skin, Dental, Vaginal, Breast augmentation) - Global Forecast ... Market is expected to reach $14.7 Billion in 2019 ... of 7.5% from 2014 to 2019. ...
(Date:3/6/2015)... N.Y. , March 6, 2015 BioSpecifics ... company developing first in class collagenase-based products marketed as ... the U.S. and XIAPEX ®  in the EU, announced ... live audio webcast at 8:30 a.m. ET on Friday, ... full year 2014 financial results and provide a corporate ...
(Date:3/6/2015)... Wash. , March 6, 2015   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... media and precision thermal shipping products for ... the Company,s fourth quarter and full year 2014 financial results ... that the Company will host a conference call and ...
(Date:3/5/2015)... , March 5, 2015   HX360 ... semi-finalists in the HX360 Innovation Challenge competition. ... will compete to be chosen as one of four ... of senior health system executives and venture capitalists during ... Innovation Challenge takes place at the 2015 HIMSS Annual ...
Breaking Biology Technology:Soft Tissue Repair Market worth $14.7 Billion in 2019 2Soft Tissue Repair Market worth $14.7 Billion in 2019 3Soft Tissue Repair Market worth $14.7 Billion in 2019 4BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2014 Financial Results on Friday, March 13, 2015 2BioLife Solutions to Report Fourth Quarter and Full Year 2014 Financial Results and Provide Business Update on March 12, 2015 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4
... Oct. 31, 2011 Neurocrine Biosciences, Inc. (NASDAQ: NBIX ... 30, 2011. For the third quarter of 2011, ... fully diluted share outstanding, compared to net income of $3.3 million, ... in 2010. For the nine months ended September 30, 2011, the ...
... (NYSE Amex: PIP ) announced today further ... SparVax™.  The new vaccine is being developed to provide ... emergency.  The Company completed its first cGMP manufacturing run ... ongoing and expected to be completed in December. ...
... Blood Pressure , aka Hypertension , is ... mostly ineffective.   Fortunately , Hypertensive patients ... methods that are both effective, inexpensive, and risk free. ... help reduce   Chronic Heart/Cardiovascular Disease patients,   ...
Cached Biology Technology:Neurocrine Biosciences Reports Third Quarter 2011 Results 2Neurocrine Biosciences Reports Third Quarter 2011 Results 3Neurocrine Biosciences Reports Third Quarter 2011 Results 4Neurocrine Biosciences Reports Third Quarter 2011 Results 5Neurocrine Biosciences Reports Third Quarter 2011 Results 6Neurocrine Biosciences Reports Third Quarter 2011 Results 7Neurocrine Biosciences Reports Third Quarter 2011 Results 8PharmAthene Progresses Second Generation rPA Anthrax Vaccine 2PharmAthene Progresses Second Generation rPA Anthrax Vaccine 3PharmAthene Progresses Second Generation rPA Anthrax Vaccine 4Drug-Free BLOOD PRESSURE Control & Medical "Take-Away" Treatment are Potential Win-Win Solutions in Health Care 2
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying to ... and potential for genomic science as a means to ... prevention and treatment.  I was honored to participate in ... precision medicine program. Since the 1980s ... of genomics—from the first sequenced genome of a free ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ... in general the State of Washington,s ... a new enrollment and central issuance system for driver,s licenses ... The project planning and development will start in January ...
(Date:1/22/2015)... Hall E -   EyeLock Inc. , a market leader ... its EyeLock ID technology integrated in a 3D printed automobile ... Ridge National Laboratory (ORNL) at the 2015 North ... is being used to validate the driver and authorize the ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... An epidemic of the viral disease nephropathia epidemica (NE) ... caused by hotter summers, milder winters and increased seedcrop ... open access International Journal of Health Geographics ... of global warming. Dr Jan Clement from the ...
... there really plenty of fish in the sea? University ... first-ever estimate of total fish biomass in our oceans: ... unrecognized but significant role in mitigating climate change by ... to a study published in tomorrow,s edition of the ...
... and biochemistry from the University of Salamanca (Spain) and ... at the Public University of Navarre, has enhanced the ... of certain fungal and bacterial genes., In concrete, ... study of microorganisms with various levels of pregenomic information ...
Cached Biology News:Global warming linked to European viral epidemic 2UBC researcher gives first-ever estimate of worldwide fish biomass and impact on climate change 2Biologist enhances use of bioinformatic tools and achieves precision in genetic annotation 2Biologist enhances use of bioinformatic tools and achieves precision in genetic annotation 3
... & visualization software. See ... samples. Combine Sequest and ... confidence. Get more detailed ... your MS/MS experiments.14 day ...
... Clone/PAD: ZMD.467. Immunogen: Synthetic peptide ... the human rat mouse dog and ... for the human occludin protein. ... lysates). Reactivity with rat mouse ...
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
Antibodies were affinity purified using epitopes specific to UBAP2L/NICE4 immobilized on solid support....
Biology Products: